Good morning, everyone, and how are you today? We are doing just fine, thank you, especially since a warm and shiny sun is enveloping the blossoming Pharmalot campus this morning. Our shortest person has left for the local schoolhouse and another short person is mimicking our official mascots by sleeping in. As for us, we are firing up the coffee kettle again, since this will be yet another hyper-busy day. Perhaps you can relate. On that note, here are some items of interest to get you going. As always, we hope you have a productive day and, of course, do keep in touch …

A former Valeant Pharmaceuticals (VRX) executive told a jury how he became concerned that one of his senior directors had a secret financial interest in a mail-order pharmacy that did business with the company, Bloomberg News reports. Laizer Kornwasser, a star government witnesses in the fraud and money-laundering trial of Gary Tanner and Andrew Davenport, who headed Philidor Rx Services, recounted how Tanner did not follow through on his responsibility to find other mail-order pharmacies with which Valeant could do business, suggesting he wanted to keep all business at Philidor.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy